emphasizing the importance of considering both metabolic and cognitive health outcomes in clinical practice. It highlights the importance of individualized treatment approaches in diabetes management, taking into account patient-specific factors such as age, sex, complications, body mass index (BMI), glyca...
Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetesQuestionnnIn patients with type 2 diabetes, how do various oral diabetes medications compare for long-term cardiovascular (CV) risk?n...
Other antidiabetic drugs The use of sodium–glucose cotransporter-2 (SGLT2) inhibitors (e.g. canagliflozin, dapagliflozin, empagliflozin) has improved the pharmacotherapy in patients with diabetes because of their antihyperglycemic effect and their cardio- and reno-protective effects [88]. Although the...
All these studies show clearly that there is a strong association between diabetes and cancer initiation and/or progression. Therefore, based on the shared molecular mechanisms between the two ailments, metformin and other diabetes drugs may have an important role in the management of human cancers,...
1 With diabetes, cardiovascular risks add to the complexity and need for interventions. The question at hand is the effectiveness of drugs versus lifestyle interventions for good health outcomes in those with diabetes. What is type 2 diabetes mellitus? Type 2 diabetes mellitus is a chronic ...
For mortality, subjects with diabetes who were using anti-diabetic drugs other than metformin or using 182.5–365.0 cDDD of metformin had higher PC mortality than non-diabetic subjects (aHR 2.01, 95% CI 1.44–2.81, p value < 0.001, and aHR 1.70, 95% CI 1.07–2.69, p value 0.025, ...
Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes mellitus for nearly 8 years. Over this period of time, it has bec
Introduction & Objective: The combination of metformin (met) with other oral antidiabetic drugs (OADs) like sodium-glucose cotransporter-2 inhibitors (SGLT-2i) is recommended by international guidelines for type 2 diabetes mellitus treatment. This systematic literature review (SLR) and meta-analysis...
Diabetes treatment and outcome Kaplan–Meier analysis showed that MET-treated diabetic patients had better survival compared to MET-free counterparts. Other therapeutic regimes were not associated with any difference in event-free survival (Fig. 2). Similarly, Cox proportional hazard model identified MET...
5.2 Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis In patients with type 1 diabetes mellitus, dapagliflozin, a component of Dapagliflozin and Metformin HCl extended-release tablets, significantly increases the risk of diabetic ketoacidosis, a life-threatening event,...